Betta Pharmaceuticals Co Ltd
SZSE:300558
Betta Pharmaceuticals Co Ltd
EPS (Diluted)
Betta Pharmaceuticals Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Betta Pharmaceuticals Co Ltd
SZSE:300558
|
EPS (Diluted)
¥1
|
CAGR 3-Years
3%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
EPS (Diluted)
¥0
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
EPS (Diluted)
¥5
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
EPS (Diluted)
¥1
|
CAGR 3-Years
12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
15%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
EPS (Diluted)
¥2
|
CAGR 3-Years
19%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
Betta Pharmaceuticals Co Ltd
Glance View
Betta Pharmaceuticals Co Ltd., established in 2003, is a dynamic player in China's rapidly evolving pharmaceutical landscape. The company made its mark with a particular focus on the research, development, production, and sale of innovative oncology drugs. Its flagship product, icotinib, a breakthrough therapy for non-small cell lung cancer, propelled Betta Pharmaceuticals into the spotlight, underpinning their pursuit of excellence in targeted cancer treatment. By capitalizing on expertise in small molecule drug discovery, Betta Pharmaceuticals transformed from a bold idea into a critical partner for healthcare providers, offering proprietary products that serve unmet medical needs across China and beyond. Driving its business model is a robust pipeline fueled by an ongoing commitment to research and innovation. Betta Pharmaceuticals thrives on its biodiverse R&D programs which are facilitated through collaborations with world-class research institutes and industry partners. The company's revenues predominantly flow from sales of its own branded oncology drugs, supplemented by royalty streams from licensing agreements. Their approach blends a careful balance of keen scientific inquiry with commercial acumen, as Betta continually reinvests in clinical trials and regulatory approvals to bring new drugs to market. Thus, the company's ability to blend innovation with practical application keeps it well-positioned amid the competitive and ever-evolving global pharmaceutical arena.
See Also
What is Betta Pharmaceuticals Co Ltd's EPS (Diluted)?
EPS (Diluted)
1.1
CNY
Based on the financial report for Sep 30, 2024, Betta Pharmaceuticals Co Ltd's EPS (Diluted) amounts to 1.1 CNY.
What is Betta Pharmaceuticals Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
15%
Over the last year, the EPS (Diluted) growth was 34%. The average annual EPS (Diluted) growth rates for Betta Pharmaceuticals Co Ltd have been 3% over the past three years , 15% over the past five years .
You don't have any saved screeners yet